GSK has revealed updated results from its phase 2b trial of its antisense drug for hepatitis B virus (HBV) infections, which reveal a sharp decline in the proportion of patients with undetectable ...
U.S. 3 Year Treasury Note 0.0130 3.5710% U.S. 5 Year Treasury Note 0.0220 3.7320% U.S. 7 Year Treasury Note 0.0290 3.9330% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback